JP7762648B2 - 安定した濃縮放射性医薬組成物 - Google Patents

安定した濃縮放射性医薬組成物

Info

Publication number
JP7762648B2
JP7762648B2 JP2022516404A JP2022516404A JP7762648B2 JP 7762648 B2 JP7762648 B2 JP 7762648B2 JP 2022516404 A JP2022516404 A JP 2022516404A JP 2022516404 A JP2022516404 A JP 2022516404A JP 7762648 B2 JP7762648 B2 JP 7762648B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
acid
salt
ascorbic acid
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022516404A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022548875A (ja
JP2022548875A5 (https=
Inventor
エフ． マリアーニ，マウリツィオ
オーランディ，フランチェスカ
フガッツァ，ロレンツァ
サッチェッティ，ロレンツォ
テデスコ，マッチャ
バルバト，ドネート
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2022548875A publication Critical patent/JP2022548875A/ja
Publication of JP2022548875A5 publication Critical patent/JP2022548875A5/ja
Priority to JP2025176508A priority Critical patent/JP2026031934A/ja
Application granted granted Critical
Publication of JP7762648B2 publication Critical patent/JP7762648B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022516404A 2019-09-16 2020-09-15 安定した濃縮放射性医薬組成物 Active JP7762648B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025176508A JP2026031934A (ja) 2019-09-16 2025-10-20 安定した濃縮放射性医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19197607 2019-09-16
EP19197607.5 2019-09-16
PCT/EP2020/075767 WO2021052960A1 (en) 2019-09-16 2020-09-15 Stable, concentrated radiopharmaceutical composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025176508A Division JP2026031934A (ja) 2019-09-16 2025-10-20 安定した濃縮放射性医薬組成物

Publications (3)

Publication Number Publication Date
JP2022548875A JP2022548875A (ja) 2022-11-22
JP2022548875A5 JP2022548875A5 (https=) 2023-09-25
JP7762648B2 true JP7762648B2 (ja) 2025-10-30

Family

ID=67981980

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022516404A Active JP7762648B2 (ja) 2019-09-16 2020-09-15 安定した濃縮放射性医薬組成物
JP2025176508A Pending JP2026031934A (ja) 2019-09-16 2025-10-20 安定した濃縮放射性医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025176508A Pending JP2026031934A (ja) 2019-09-16 2025-10-20 安定した濃縮放射性医薬組成物

Country Status (11)

Country Link
US (2) US20220401593A1 (https=)
EP (1) EP4031193A1 (https=)
JP (2) JP7762648B2 (https=)
KR (1) KR20220063218A (https=)
CN (1) CN114728088A (https=)
AR (1) AR119974A1 (https=)
AU (1) AU2020349002B2 (https=)
CA (1) CA3154302A1 (https=)
IL (1) IL291315A (https=)
TW (1) TW202123976A (https=)
WO (1) WO2021052960A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4442285A1 (en) * 2021-11-30 2024-10-09 Nihon Medi-Physics Co., Ltd. Stabilized radiopharmaceutical composition
CN114404618A (zh) * 2022-03-28 2022-04-29 北京先通国际医药科技股份有限公司 放射性药物水溶液及其用途
CN114404619A (zh) * 2022-03-28 2022-04-29 北京先通国际医药科技股份有限公司 放射性药物水溶液及其制备方法和用途
CN116920129A (zh) * 2022-04-02 2023-10-24 北京先通国际医药科技股份有限公司 放射性药物水溶液及其制备方法和用途
JP2026505341A (ja) 2023-02-08 2026-02-13 ノバルティス アーゲー 神経膠芽腫を治療するための方法
IL322257A (en) 2023-02-23 2025-09-01 Novartis Ag Methods of treating breast cancer
CN121793988A (zh) 2023-09-13 2026-04-03 东丽株式会社 癌的治疗、预防和/或诊断用药物组合物
TW202527951A (zh) 2023-12-15 2025-07-16 瑞士商諾華公司 用於治療乳腺癌的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006528644A (ja) 2003-07-24 2006-12-21 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 安定な放射性医薬品組成物およびその製法
JP2015533119A (ja) 2012-09-25 2015-11-19 アドヴァンスド アクセレレーター アプリケーションズ ユー・エス・エイ インコーポレイテッドＡｄｖａｎｃｅｄ Ａｃｃｅｌｅｒａｔｏｒ Ａｐｐｌｉｃａｔｉｏｎｓ ＵＳＡ， Ｉｎｃ． Ｇｒｐｒ陽性ガンの検出、診断及び治療のためのｇｒｐｒアンタゴニスト

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008009444A1 (en) 2006-07-19 2008-01-24 Van Dulmen, Adrianus, A. Use of ethanol for stabilizing a single-vial liquid formulation of a radiolabeled peptide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006528644A (ja) 2003-07-24 2006-12-21 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 安定な放射性医薬品組成物およびその製法
JP2015533119A (ja) 2012-09-25 2015-11-19 アドヴァンスド アクセレレーター アプリケーションズ ユー・エス・エイ インコーポレイテッドＡｄｖａｎｃｅｄ Ａｃｃｅｌｅｒａｔｏｒ Ａｐｐｌｉｃａｔｉｏｎｓ ＵＳＡ， Ｉｎｃ． Ｇｒｐｒ陽性ガンの検出、診断及び治療のためのｇｒｐｒアンタゴニスト

Also Published As

Publication number Publication date
AR119974A1 (es) 2022-01-26
EP4031193A1 (en) 2022-07-27
WO2021052960A1 (en) 2021-03-25
US20220401593A1 (en) 2022-12-22
JP2022548875A (ja) 2022-11-22
IL291315A (en) 2022-05-01
CN114728088A (zh) 2022-07-08
KR20220063218A (ko) 2022-05-17
TW202123976A (zh) 2021-07-01
US20250332301A1 (en) 2025-10-30
JP2026031934A (ja) 2026-02-25
AU2020349002A1 (en) 2022-04-28
AU2020349002B2 (en) 2024-05-02
CA3154302A1 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
JP7762648B2 (ja) 安定した濃縮放射性医薬組成物
TWI878344B (zh) 放射性標記grpr拮抗劑之方法及其套組
JP2023546525A (ja) 前立腺特異的膜抗原を標的とする化合物及びその調製方法と応用
JP2008266342A (ja) 部位特異的ターゲッティング用の放射性標識ペプチド組成物
JP7541532B2 (ja) 診断及び治療のための新規な放射性標識されたｃｘｃｒ４を標的とする化合物
JP2024045147A (ja) 放射性医薬品用のソマトスタチンアナログを含む組成物
WO2025246177A1 (zh) 一种靶向fap的二聚化合物及其探针和应用
JP2025506001A (ja) ２２５－アクチニウム標識錯体及びビスマス封鎖剤を含む医薬組成物
AU2020356262B2 (en) Radiolabelled GRPR-antagonist for use as theragnostic
JP7802851B2 (ja) 放射性標識されたｇｐｒｐアンタゴニスト及び界面活性剤を含む医薬組成物
RU2839656C1 (ru) Стабильная концентрированная радиофармацевтическая композиция
RU2855011C1 (ru) Способы мечения радиоактивными изотопами антагонистов grpr и наборы на для их осуществления

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230913

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250401

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250924

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251007

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251020

R150 Certificate of patent or registration of utility model

Ref document number: 7762648

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150